P1130: FRONTLINE BRENTUXIMAB VEDOTIN AND CHP (A+CHP) IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA WITH LESS THAN 10% CD30 EXPRESSION: INITIAL SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY SGN35-032

• Swaminathan Iyer,
• Deepa Jagadeesh,
• Eva Domingo Domènech,
• Fabio Benedetti,
• Antonia Rodriguez Izquierdo,
• Kamal Bouabdallah,
• Umberto Vitolo,
• Tim Illidge,
• Jingmin Liu,
• Scott Knowles,
• Steven Horwitz

Affiliations

Swaminathan Iyer

1 The University of Texas MD Anderson Cancer Center, Houston,TX, United States

Deepa Jagadeesh

2 Cleveland Clinic Taussig Cancer Center, Cleveland, OH, United States

Eva Domingo Domènech

3 Institut Català d’Oncologia - Hospital Duran i Reynals, Barcelona, Spain

Fabio Benedetti

4 University of Verona, Verona, Italy

Antonia Rodriguez Izquierdo

5 Hospital 12 de Octubre, Madrid, Spain

Kamal Bouabdallah

6 CHU Haut-Leveque, Service d’hematologie clinique et therapie cellulaire, Pessac, France

Umberto Vitolo

7 Oncological Institute Candiolo, Candiolo, Italy

Tim Illidge

8 The Christie NHS Foundation Trust, Manchester, United Kingdom

Jingmin Liu

9 Seagen Inc., Bothell, WA, United States

Scott Knowles

9 Seagen Inc., Bothell, WA, United States

Steven Horwitz

10 Memorial Sloan Kettering Cancer Center New York, New York, NY, United States